| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 33 | 2024 | 794 | 6.080 |
Why?
|
| MicroRNAs | 8 | 2022 | 386 | 2.940 |
Why?
|
| Transcription Factors | 8 | 2021 | 653 | 2.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2022 | 781 | 2.040 |
Why?
|
| Prostate | 7 | 2024 | 136 | 1.350 |
Why?
|
| Breast Neoplasms | 8 | 2022 | 1426 | 1.070 |
Why?
|
| Cell Line, Tumor | 26 | 2023 | 2128 | 0.990 |
Why?
|
| Prostatic Hyperplasia | 1 | 2024 | 33 | 0.950 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2023 | 11 | 0.930 |
Why?
|
| Male | 41 | 2024 | 18870 | 0.920 |
Why?
|
| Cell Nucleus | 3 | 2014 | 351 | 0.920 |
Why?
|
| Humans | 59 | 2024 | 34853 | 0.910 |
Why?
|
| Cell Movement | 5 | 2016 | 545 | 0.900 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2023 | 91 | 0.870 |
Why?
|
| Cadherins | 6 | 2016 | 82 | 0.760 |
Why?
|
| Neoplasm Metastasis | 8 | 2021 | 211 | 0.750 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 203 | 0.710 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2010 | 29 | 0.650 |
Why?
|
| Proteomics | 4 | 2022 | 302 | 0.620 |
Why?
|
| Receptors, Androgen | 1 | 2018 | 122 | 0.610 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 13 | 0.600 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 32 | 0.560 |
Why?
|
| Cell Proliferation | 10 | 2021 | 1149 | 0.540 |
Why?
|
| Epithelial Cells | 4 | 2017 | 366 | 0.540 |
Why?
|
| Neoplasms | 6 | 2023 | 1033 | 0.540 |
Why?
|
| Antigens, CD | 2 | 2016 | 116 | 0.540 |
Why?
|
| Neoplastic Stem Cells | 2 | 2013 | 74 | 0.540 |
Why?
|
| Cell Adhesion | 4 | 2016 | 209 | 0.530 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 106 | 0.510 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 82 | 0.490 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2014 | 32 | 0.490 |
Why?
|
| Neoplasm Invasiveness | 6 | 2016 | 247 | 0.480 |
Why?
|
| Mice | 14 | 2023 | 5668 | 0.450 |
Why?
|
| Cell Lineage | 1 | 2013 | 88 | 0.440 |
Why?
|
| Antineoplastic Agents | 5 | 2014 | 756 | 0.430 |
Why?
|
| Apoptosis | 9 | 2017 | 1317 | 0.430 |
Why?
|
| DNA Methylation | 3 | 2022 | 301 | 0.420 |
Why?
|
| Peptides | 3 | 2023 | 308 | 0.410 |
Why?
|
| Dioxoles | 5 | 2012 | 6 | 0.410 |
Why?
|
| Telomerase | 1 | 2011 | 40 | 0.400 |
Why?
|
| Isoquinolines | 5 | 2012 | 40 | 0.390 |
Why?
|
| Glycoproteins | 1 | 2011 | 100 | 0.390 |
Why?
|
| Animals | 19 | 2023 | 14307 | 0.380 |
Why?
|
| Duffy Blood-Group System | 2 | 2021 | 2 | 0.380 |
Why?
|
| Hepatocytes | 2 | 2007 | 74 | 0.370 |
Why?
|
| Receptors, Cell Surface | 2 | 2021 | 135 | 0.360 |
Why?
|
| Kidney Transplantation | 2 | 2020 | 85 | 0.340 |
Why?
|
| Noscapine | 3 | 2014 | 11 | 0.340 |
Why?
|
| Neoplasm Transplantation | 4 | 2021 | 114 | 0.330 |
Why?
|
| Peptide Fragments | 1 | 2010 | 298 | 0.330 |
Why?
|
| Female | 17 | 2022 | 19873 | 0.330 |
Why?
|
| Signal Transduction | 10 | 2022 | 1802 | 0.320 |
Why?
|
| Mutation | 2 | 2022 | 1023 | 0.320 |
Why?
|
| Epigenesis, Genetic | 2 | 2022 | 198 | 0.310 |
Why?
|
| Bioreactors | 1 | 2007 | 21 | 0.300 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 99 | 0.290 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 195 | 0.290 |
Why?
|
| Healthcare Disparities | 3 | 2022 | 446 | 0.280 |
Why?
|
| Flow Cytometry | 3 | 2016 | 392 | 0.280 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2021 | 84 | 0.270 |
Why?
|
| Mice, Nude | 5 | 2021 | 323 | 0.270 |
Why?
|
| Epidermal Growth Factor | 2 | 2018 | 63 | 0.270 |
Why?
|
| Hormone Antagonists | 1 | 2005 | 15 | 0.260 |
Why?
|
| RNA, Messenger | 2 | 2022 | 1152 | 0.260 |
Why?
|
| Middle Aged | 8 | 2021 | 9642 | 0.260 |
Why?
|
| Lymphatic Metastasis | 2 | 2016 | 63 | 0.250 |
Why?
|
| Axonemal Dyneins | 1 | 2024 | 5 | 0.250 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2024 | 5 | 0.250 |
Why?
|
| Protein Transport | 3 | 2014 | 286 | 0.240 |
Why?
|
| Drug Delivery Systems | 3 | 2017 | 182 | 0.240 |
Why?
|
| Coculture Techniques | 3 | 2010 | 96 | 0.240 |
Why?
|
| Adenocarcinoma | 3 | 2010 | 239 | 0.240 |
Why?
|
| Cyclodextrins | 2 | 2014 | 9 | 0.240 |
Why?
|
| Trans Fatty Acids | 1 | 2023 | 5 | 0.240 |
Why?
|
| Gallium Radioisotopes | 1 | 2023 | 2 | 0.230 |
Why?
|
| Bleomycin | 1 | 2023 | 18 | 0.230 |
Why?
|
| Living Donors | 2 | 2020 | 15 | 0.230 |
Why?
|
| Aged | 5 | 2016 | 6448 | 0.230 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2023 | 36 | 0.230 |
Why?
|
| Receptors, Calcitriol | 1 | 2023 | 59 | 0.220 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 336 | 0.210 |
Why?
|
| Alabama | 2 | 2020 | 46 | 0.210 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 69 | 0.210 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 27 | 0.210 |
Why?
|
| Endonucleases | 1 | 2021 | 18 | 0.200 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2021 | 4 | 0.200 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2021 | 4 | 0.200 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 325 | 0.200 |
Why?
|
| DNA Repair | 1 | 2022 | 181 | 0.200 |
Why?
|
| Immunotherapy | 1 | 2021 | 91 | 0.190 |
Why?
|
| Databases, Genetic | 2 | 2021 | 90 | 0.190 |
Why?
|
| Nanoparticles | 2 | 2017 | 294 | 0.190 |
Why?
|
| Donor Selection | 1 | 2020 | 7 | 0.190 |
Why?
|
| Patient Advocacy | 1 | 2020 | 20 | 0.180 |
Why?
|
| Quality of Life | 1 | 2024 | 459 | 0.180 |
Why?
|
| Green Fluorescent Proteins | 2 | 2013 | 200 | 0.180 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2020 | 33 | 0.180 |
Why?
|
| Cytokines | 1 | 2023 | 569 | 0.180 |
Why?
|
| United States | 5 | 2023 | 3894 | 0.180 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 17 | 0.180 |
Why?
|
| Glycolysis | 2 | 2016 | 66 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 176 | 0.170 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 269 | 0.170 |
Why?
|
| Health Services Accessibility | 2 | 2022 | 531 | 0.170 |
Why?
|
| Stromal Cells | 2 | 2011 | 45 | 0.170 |
Why?
|
| Behavioral Research | 1 | 2019 | 37 | 0.170 |
Why?
|
| Chemokines | 1 | 2019 | 89 | 0.170 |
Why?
|
| Minority Health | 1 | 2019 | 81 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2023 | 638 | 0.160 |
Why?
|
| Quinazolines | 1 | 2018 | 31 | 0.160 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2017 | 13 | 0.160 |
Why?
|
| Minority Groups | 2 | 2022 | 537 | 0.160 |
Why?
|
| Gene Silencing | 1 | 2018 | 143 | 0.150 |
Why?
|
| Ferric Compounds | 1 | 2017 | 49 | 0.150 |
Why?
|
| Adult | 4 | 2019 | 11034 | 0.150 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 39 | 0.150 |
Why?
|
| Serine Endopeptidases | 1 | 2017 | 36 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 133 | 0.150 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1056 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2016 | 79 | 0.140 |
Why?
|
| Proteome | 1 | 2017 | 132 | 0.140 |
Why?
|
| Microscopy, Fluorescence | 3 | 2021 | 240 | 0.140 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 71 | 0.140 |
Why?
|
| Autoantibodies | 1 | 2016 | 103 | 0.140 |
Why?
|
| Cell Communication | 2 | 2007 | 93 | 0.130 |
Why?
|
| Galactans | 1 | 2014 | 2 | 0.130 |
Why?
|
| Mannans | 1 | 2014 | 3 | 0.130 |
Why?
|
| Plant Gums | 1 | 2014 | 7 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 480 | 0.130 |
Why?
|
| Microspheres | 1 | 2014 | 45 | 0.130 |
Why?
|
| Mice, SCID | 2 | 2011 | 143 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2019 | 371 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 605 | 0.120 |
Why?
|
| Phenotype | 2 | 2014 | 650 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2014 | 94 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 74 | 0.120 |
Why?
|
| Keratin-14 | 1 | 2013 | 1 | 0.120 |
Why?
|
| Keratin-5 | 1 | 2013 | 8 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 484 | 0.120 |
Why?
|
| Integrases | 1 | 2013 | 27 | 0.120 |
Why?
|
| Sex Factors | 1 | 2016 | 859 | 0.110 |
Why?
|
| Ghana | 2 | 2023 | 27 | 0.110 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 550 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2021 | 185 | 0.110 |
Why?
|
| Subcellular Fractions | 1 | 2012 | 72 | 0.110 |
Why?
|
| Caspase 3 | 2 | 2010 | 194 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 468 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2007 | 1534 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 56 | 0.110 |
Why?
|
| Ipomoea batatas | 1 | 2011 | 6 | 0.100 |
Why?
|
| Cell Aggregation | 1 | 2011 | 14 | 0.100 |
Why?
|
| Cell Cycle | 1 | 2013 | 309 | 0.100 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 87 | 0.100 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 81 | 0.100 |
Why?
|
| NF-kappa B | 1 | 2014 | 306 | 0.100 |
Why?
|
| Cell Separation | 1 | 2011 | 91 | 0.100 |
Why?
|
| ADAM Proteins | 1 | 2011 | 15 | 0.100 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 608 | 0.100 |
Why?
|
| Plant Leaves | 1 | 2011 | 110 | 0.100 |
Why?
|
| Antitussive Agents | 1 | 2010 | 4 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2022 | 1961 | 0.100 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2010 | 9 | 0.100 |
Why?
|
| Epithelium | 1 | 2011 | 74 | 0.100 |
Why?
|
| Gene Expression | 1 | 2014 | 639 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2010 | 984 | 0.100 |
Why?
|
| Cell Survival | 4 | 2017 | 818 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 600 | 0.100 |
Why?
|
| Tubulin Modulators | 1 | 2010 | 16 | 0.090 |
Why?
|
| Disease Progression | 1 | 2012 | 580 | 0.090 |
Why?
|
| Rats | 2 | 2007 | 3261 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2009 | 82 | 0.080 |
Why?
|
| Teniposide | 1 | 2008 | 1 | 0.080 |
Why?
|
| Mesoderm | 1 | 2008 | 70 | 0.080 |
Why?
|
| Endothelial Cells | 2 | 2012 | 296 | 0.080 |
Why?
|
| Lymphoma | 1 | 2008 | 37 | 0.080 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2008 | 42 | 0.080 |
Why?
|
| Tubulin | 1 | 2008 | 80 | 0.080 |
Why?
|
| Liver Circulation | 1 | 2007 | 1 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2021 | 184 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2011 | 486 | 0.080 |
Why?
|
| Perfusion | 1 | 2007 | 31 | 0.080 |
Why?
|
| Rats, Transgenic | 1 | 2007 | 27 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2009 | 391 | 0.070 |
Why?
|
| Equipment Design | 1 | 2007 | 127 | 0.070 |
Why?
|
| Mitochondria | 1 | 2010 | 454 | 0.070 |
Why?
|
| Carcinoma | 1 | 2007 | 94 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 2333 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2005 | 170 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2005 | 70 | 0.060 |
Why?
|
| Calorimetry, Differential Scanning | 2 | 2014 | 29 | 0.060 |
Why?
|
| Fatty Acid Desaturases | 1 | 2023 | 4 | 0.060 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 2 | 2014 | 67 | 0.060 |
Why?
|
| Risk Factors | 2 | 2021 | 3414 | 0.060 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2023 | 52 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2023 | 197 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2023 | 79 | 0.060 |
Why?
|
| Fatty Acids | 1 | 2023 | 118 | 0.050 |
Why?
|
| Thromboxane B2 | 1 | 2022 | 8 | 0.050 |
Why?
|
| Thromboxane A2 | 1 | 2022 | 18 | 0.050 |
Why?
|
| Chromatin | 1 | 2023 | 164 | 0.050 |
Why?
|
| Young Adult | 1 | 2012 | 4012 | 0.050 |
Why?
|
| Endoplasmic Reticulum | 1 | 2022 | 101 | 0.050 |
Why?
|
| Aspirin | 1 | 2022 | 45 | 0.050 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2021 | 4 | 0.050 |
Why?
|
| Carcinoma, Large Cell | 1 | 2021 | 3 | 0.050 |
Why?
|
| Automation, Laboratory | 1 | 2021 | 3 | 0.050 |
Why?
|
| Internationality | 1 | 2021 | 29 | 0.050 |
Why?
|
| Tumor Escape | 1 | 2021 | 12 | 0.050 |
Why?
|
| Tissue Array Analysis | 1 | 2021 | 65 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2021 | 123 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2021 | 67 | 0.050 |
Why?
|
| Alleles | 1 | 2021 | 284 | 0.050 |
Why?
|
| Carboxylic Acids | 1 | 2020 | 12 | 0.050 |
Why?
|
| Ghrelin | 1 | 2020 | 12 | 0.050 |
Why?
|
| G2 Phase | 2 | 2010 | 25 | 0.050 |
Why?
|
| Limit of Detection | 1 | 2020 | 56 | 0.050 |
Why?
|
| Chromatography, Affinity | 1 | 2020 | 64 | 0.050 |
Why?
|
| Nigeria | 1 | 2019 | 74 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 109 | 0.040 |
Why?
|
| Macrophages | 1 | 2023 | 431 | 0.040 |
Why?
|
| Mitosis | 2 | 2010 | 97 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2019 | 75 | 0.040 |
Why?
|
| Genotype | 1 | 2021 | 641 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2009 | 72 | 0.040 |
Why?
|
| Focus Groups | 1 | 2019 | 307 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2019 | 356 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 707 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 173 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 316 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 322 | 0.040 |
Why?
|
| Lung | 1 | 2021 | 413 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2021 | 727 | 0.040 |
Why?
|
| Research Personnel | 1 | 2019 | 133 | 0.040 |
Why?
|
| Cultural Diversity | 1 | 2019 | 158 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2020 | 406 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 114 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2017 | 48 | 0.040 |
Why?
|
| Surface Properties | 1 | 2017 | 121 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2021 | 1422 | 0.040 |
Why?
|
| Particle Size | 1 | 2017 | 200 | 0.040 |
Why?
|
| Cell Line | 2 | 2010 | 1289 | 0.040 |
Why?
|
| Endocytosis | 1 | 2017 | 104 | 0.040 |
Why?
|
| Antibodies, Neoplasm | 1 | 2016 | 16 | 0.040 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2016 | 33 | 0.040 |
Why?
|
| Incidence | 1 | 2019 | 882 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 901 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2017 | 342 | 0.040 |
Why?
|
| Cell Death | 1 | 2017 | 260 | 0.040 |
Why?
|
| Time Factors | 1 | 2021 | 1681 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2016 | 56 | 0.040 |
Why?
|
| Iron | 1 | 2017 | 204 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2017 | 347 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 255 | 0.030 |
Why?
|
| beta-Cyclodextrins | 1 | 2014 | 22 | 0.030 |
Why?
|
| HT29 Cells | 1 | 2014 | 40 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2015 | 59 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2015 | 71 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2015 | 49 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2015 | 180 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2014 | 109 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 522 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2019 | 583 | 0.030 |
Why?
|
| Paxillin | 1 | 2012 | 5 | 0.030 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2012 | 22 | 0.030 |
Why?
|
| X-Ray Diffraction | 1 | 2012 | 49 | 0.030 |
Why?
|
| Centrosome | 1 | 2012 | 28 | 0.030 |
Why?
|
| Solubility | 1 | 2012 | 115 | 0.030 |
Why?
|
| Cell Polarity | 1 | 2012 | 53 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2014 | 490 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 2561 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 164 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2011 | 126 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 2011 | 12 | 0.030 |
Why?
|
| Microtubules | 1 | 2012 | 113 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2014 | 878 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 5 | 0.020 |
Why?
|
| Superoxides | 1 | 2011 | 51 | 0.020 |
Why?
|
| Integrins | 1 | 2011 | 49 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 281 | 0.020 |
Why?
|
| Androgens | 1 | 2010 | 87 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 136 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 32 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2009 | 72 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2009 | 91 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2009 | 107 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 242 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 209 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 146 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2009 | 423 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 1442 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 649 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2009 | 420 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 166 | 0.020 |
Why?
|
| Protein Binding | 1 | 2008 | 913 | 0.020 |
Why?
|